ArticleJournal of neuro-oncology1997
Glucocorticoid-induced long-term remission in primary cerebral lymphoma: case report and review of the literature.
Article in Journal of neuro-oncology, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Radiological response of primary central nervous system lymphoma after corticosteroid therapy and its predictive value on overall survival: a multicenter study.Journal of neuro-oncology · 2026Article
- Lymphomas of Central Nervous System.Advances in experimental medicine and biology · 2023Article
- Article
- An Update on Neurosurgical Management of Primary CNS Lymphoma in Immunocompetent Patients.Frontiers in oncology · 2022Review
- Article
- Use of FDG-PET/CT for systemic assessment of suspected primary central nervous system lymphoma: a LOC study.Journal of neuro-oncology · 2020Article
- Cell-Block cytology in diagnosis of primary central nervous system lymphoma: A case report.Medicine · 2020Article
- The Impact of Early Corticosteroid Pretreatment Before Initiation of Chemotherapy in Patients With Primary Central Nervous System Lymphoma.Neurosurgery · 2019Observational
- Recurrent Epstein-Barr Virus-positive (EBV+) Primary Central Nervous System Lymphoma (PCNSL) in a Patient with Clinical Features of Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids (CLIPPERS).Internal medicine (Tokyo, Japan) · 2019Article
- The Diagnosis and Treatment of Primary CNS Lymphoma.Deutsches Arzteblatt international · 2018Article
- The Challenge of Primary Central Nervous System Lymphoma.Hematology/oncology clinics of North America · 2016Review
- New approaches in primary central nervous system lymphoma.Chinese clinical oncology · 2015Review
- Progress in central nervous system lymphomas.British journal of haematology · 2014Review
- How I treat CNS lymphomas.Blood · 2013Article
- A rare case of vomiting: fourth ventricular B-cell lymphoma.Journal of neuro-oncology · 2009Article
- Treatment of primary central nervous system lymphoma.Current treatment options in neurology · 2007Article
- Treatment of primary central nervous system lymphoma.Current neurology and neuroscience reports · 2007Review
- Primary Central Nervous System Lymphoma (PCNSL) occurring in pregnancy.Journal of neurology · 2005Article
- Primary Central Nervous System Lymphoma.Current treatment options in neurology · 2003Article
- Primary central nervous system lymphoma: from clinical presentation to diagnosis.Journal of neuro-oncology · 1999Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a 25-year old immunocompetent woman with a high grade primary non-Hodgkin's lymphoma of the central nervous system (PNHL-CNS) in whom the administration of dexamethasone alone during three months produced a complete clinical and radiological response lasting over four years. If complete remission of PNHL-CNS induced by glucocorticoids are well known, the opportunity to observe glucocorticoid-induced remission for a long period of time without radio- and chemotherapy is rare. Only nine other cases of PNHL-CNS with complete remission induced by glucocorticoids lasting from 6 to 60 months, were found in the literature and are summarized here. Duration of glucocorticoids therapeutic effect in PNHL-CNS is probably underestimated. Glucocorticoids cannot be recommended as sole initial treatment for PNHL-CNS. However, we suggest standard therapies to be delayed in those patients responding completely to glucocorticoids where radio- and chemotherapy should be contraindicated (kidney, liver, bone marrow failure, pregnancy).
Indexed as
Identifiers
9049864What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.